- Home
- TSHA vs BWMN Comparison
TSHA vs BWMN Comparison
Compare TSHA & BWMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- BWMN
- Stock Information
- Founded
- TSHA 2019
- BWMN 1995
- Country
- TSHA United States
- BWMN United States
- Employees
- TSHA N/A
- BWMN N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- BWMN Military/Government/Technical
- Sector
- TSHA Health Care
- BWMN Consumer Discretionary
- Exchange
- TSHA Nasdaq
- BWMN Nasdaq
- Market Cap
- TSHA 728.4M
- BWMN 737.1M
- IPO Year
- TSHA 2020
- BWMN 2021
- Fundamental
- Price
- TSHA $3.02
- BWMN $41.82
- Analyst Decision
- TSHA Strong Buy
- BWMN Strong Buy
- Analyst Count
- TSHA 7
- BWMN 3
- Target Price
- TSHA $8.71
- BWMN $38.17
- AVG Volume (30 Days)
- TSHA 3.5M
- BWMN 131.6K
- Earning Date
- TSHA 11-12-2025
- BWMN 11-05-2025
- Dividend Yield
- TSHA N/A
- BWMN N/A
- EPS Growth
- TSHA N/A
- BWMN N/A
- EPS
- TSHA N/A
- BWMN 0.61
- Revenue
- TSHA $8,098,000.00
- BWMN $462,176,000.00
- Revenue This Year
- TSHA N/A
- BWMN $17.89
- Revenue Next Year
- TSHA N/A
- BWMN $6.96
- P/E Ratio
- TSHA N/A
- BWMN $68.04
- Revenue Growth
- TSHA N/A
- BWMN 19.48
- 52 Week Low
- TSHA $1.05
- BWMN $17.90
- 52 Week High
- TSHA $3.40
- BWMN $43.21
- Technical
- Relative Strength Index (RSI)
- TSHA 51.14
- BWMN 61.49
- Support Level
- TSHA $3.16
- BWMN $40.00
- Resistance Level
- TSHA $2.99
- BWMN $41.89
- Average True Range (ATR)
- TSHA 0.18
- BWMN 1.15
- MACD
- TSHA -0.01
- BWMN -0.34
- Stochastic Oscillator
- TSHA 38.21
- BWMN 56.79
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About BWMN Bowman Consulting Group Ltd.
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.